Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial.
Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial.
复制标题
DOI：
10.1093/infdis/jiab035
复制
发表时间：
2021-04-23
期刊：
影响因子：
--
通讯作者：
Bold TD
中科院分区：
文献类型：
--
作者：
Thiede JM;Gress AR;Libby SD;Ronayne CE;Matchett WE;Noren B;Billings JL;Menachery VD;Langlois RA;Kline S;Bold TD
2019冠状病毒病（COVID-19）的结果与宿主免疫反应有关，可能会受到抗病毒治疗的影响。我们研究了在我们中心登记的ACTT-1研究参与者的抗体和细胞因子应答。我们研究了19名住院的COVID-19成人患者的血清标本，这些患者被随机分配接受Remdesivir或安慰剂治疗。我们评估了严重急性呼吸综合征冠状病毒2型抗体应答，并确定细胞因子的签名，使用分层聚类。我们没有发现与remdesivir治疗相关的明确的免疫学趋势。7名参与者在研究入组时最初为血清阴性，该组所有4例死亡均发生在最近的症状发作中。我们确定了3种主要的细胞因子特征，证明了不同的疾病轨迹。在2019年瑞德西韦治疗冠状病毒病的ACTT-1研究的参与者中，我们进行了免疫学分析。研究入组时血清抗体活性的初始缺失与死亡率相关，纵向疾病轨迹以血清细胞因子特征为特征。
Coronavirus disease 2019 (COVID-19) outcomes are linked to host immune responses and may be affected by antiviral therapy. We investigated antibody and cytokine responses in ACTT-1 study participants enrolled at our center. We studied serum specimens from 19 hospitalized adults with COVID-19 randomized to treatment with remdesivir or placebo. We assessed severe acute respiratory syndrome coronavirus 2 antibody responses and identified cytokine signatures, using hierarchical clustering. We identified no clear immunologic trends attributable to remdesivir treatment. Seven participants were initially seronegative at study enrollment, and all 4 deaths occurred in this group with more recent symptom onset. We identified 3 dominant cytokine signatures, demonstrating different disease trajectories. Among participants in the ACTT-1 study of remdesivir treatment of coronavirus disease 2019, we performed immunologic profiling. Initial absence of serum antibody activity on study enrollment was associated with mortality rate, with longitudinal disease trajectories characterized by serum cytokine signature.
登录
查看更多内容
影响因子：
2.9
作者：
Gniadek TJ;Thiede JM;Matchett WE;Gress AR;Pape KA;Fiege JK;Jenkins MK;Menachery VD;Langlois RA;Bold TD
通讯作者：
Bold TD
影响因子：
82.9
作者：
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者：
Huang, Ai-Long
影响因子：
82.9
作者：
Del Valle DM;Kim-Schulze S;Huang HH;Beckmann ND;Nirenberg S;Wang B;Lavin Y;Swartz TH;Madduri D;Stock A;Marron TU;Xie H;Patel M;Tuballes K;Van Oekelen O;Rahman A;Kovatch P;Aberg JA;Schadt E;Jagannath S;Mazumdar M;Charney AW;Firpo-Betancourt A;Mendu DR;Jhang J;Reich D;Sigel K;Cordon-Cardo C;Feldmann M;Parekh S;Merad M;Gnjatic S
通讯作者：
Gnjatic S
影响因子：
16.6
作者：
Muruato, Antonio E.;Fontes-Garfias, Camila R.;Shi, Pei-Yong
通讯作者：
Shi, Pei-Yong
影响因子：
24.8
作者：
Premkumar, Lakshmanane;Segovia-Chumbez, Bruno;de Silva, Aravinda M.
通讯作者：
de Silva, Aravinda M.